[Clinical study of a low-dose contraceptive--Femodene].
The authors present their clinical experience with a low-dose monophasic contraceptive consisting of 30 mcg ethinylestradiol and 75 mcg a gestagen--gestodene (Femoden, Schering). 112 menstrual cycles of 22 women in fertile age were followed. The results show 100% contraception, a good control of the menstrual cycle and tolerance of the preparation.
Rachev
E
E
Damianov
L
L
Dukovski
A
A
Katsarova
M
M
D000328:Adult; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D003280:Contraceptives, Oral, Synthetic / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D004997:Ethinyl Estradiol / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D005260:Female; D006801:Humans; D008597:Menstrual Cycle / Q000187:drug effects; D009652:Norpregnenes / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology
D003277:Contraceptives, Oral, Combined; D003280:Contraceptives, Oral, Synthetic; D009652:Norpregnenes; C055368:Femovan; D004997:Ethinyl Estradiol
Klinichno prouchvane na niskodoziran kontratseptiv--Femoden.